Navigation Links
Neurocrine Biosciences Completes 'Petal Study' Treatment Phase for Endometriosis


SAN DIEGO, June 17 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the elagolix 0603 Phase IIb trial (Petal Study) has completed the 6-month treatment phase. The last subject completed her Week 24 study visit in early June. This Phase IIb trial assesses the impact of elagolix treatment on bone mineral density (BMD) as the primary endpoint using Dual Energy X-ray Absorptiometry (DXA) scans to document any change from baseline. In addition, efficacy assessments of endometriosis symptoms using the Composite Pelvic Sign and Symptoms Score (CPSSS) and Visual Analog Scale (VAS) are secondary endpoints.

"The Petal Study is an important trial for the elagolix program," says Christopher O'Brien, MD, Chief Medical Officer and Senior Vice President of Clinical Development. "For the first time we have the opportunity to examine the relationship between estradiol, n-telopeptide (a biomarker for bone resorption), elagolix plasma concentrations and BMD using DXA. We included a positive control, Depo-Provera, as one treatment arm in this randomized, double-blind, active comparator controlled trial to provide confidence that the trial would not miss subtle treatment-related effects," stated Dr. O'Brien.

"The recruitment process for the Petal Study confirms that endometriosis is an important, unmet medical need afflicting many women in the United States. Our call center received over 8,000 calls expressing interest in new treatments for endometriosis," reports Dr. O'Brien. A total of 252 women with endometriosis were randomized to one of three treatment arms: oral elagolix 150mg once daily, oral elagolix 75mg twice daily or Depo-Provera injection every 3 months. After completing the 6-month treatment phase, subjects continue in the blinded trial for additional DXA, safety and clinical evaluations at 6 and 12 months post treatment per Food and Drug Administration (FDA) recommendations. The collection of treatment phase data, quality control processing and statistical analyses will take place over the upcoming weeks. As announced previously, Neurocrine is on track to report this treatment phase topline data in early September 2008.

The Petal Study will contribute to the extensive data set of 10 Phase I studies, 2 Phase IIa studies and 3 Phase IIb studies that will serve as the basis for end-of-phase II discussions anticipated in 2009 with the Division of Reproductive and Urologic Drug Products at the FDA.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome (IBS), anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's GnRH program and R & D pipeline and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's GnRH program include, but are not limited to, risk that the Company's elagolix Phase II clinical trials will fail to demonstrate that elagolix is safe and effective; risk that elagolix will not proceed to later stage clinical trials; risk associated with the Company's dependence on corporate collaborators for development, commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2007 and on Form 10-Q for the period ended March 31, 2008. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Neurocrine Biosciences Reports First Quarter 2008 Results
2. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
3. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
4. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
5. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
6. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
7. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
8. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
9. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
10. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
11. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
Post Your Comments:
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
(Date:11/26/2015)... Research and Markets ( ) has ... Market by Type (Dressings, Therapy Devices, Active Wound Care), ... Facility), and Geography - Global Forecast to 2020" ... --> The purpose of this report ... the global advanced wound care market. It involves deep ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> adds "Global ... and "Investigation Report on China Repaglinide ... 2021 forecasts data and information to ... . --> ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end ... Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... and prominent nonprofit healthcare organizations in the country. They have overseen financial turnarounds, ... and helped advance the healthcare industry as a whole through their advocacy and ...
(Date:11/26/2015)... Vegas, NV (PRWEB) , ... November 26, 2015 , ... ... shopping strategy. Many customers choose to buy during the Black Friday and Cyber ... gifts. Shoppers don’t need to search the Internet high and low to find the ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is updating their record books ... their 6,000th free flap breast reconstruction surgery! , “What an accomplishment for the PRMA ... rebuild lives and it’s an honor to have served all of these women.” , ...
(Date:11/25/2015)... OAK BROOK, Ill. (PRWEB) , ... November 25, ... ... sometimes larger and potentially more aggressive than those found on mammography, according to ... cases MRI findings of additional cancers not seen on mammography may necessitate a ...
Breaking Medicine News(10 mins):